H.C. Wainwright upgraded Kazia Therapeutics to Buy from Neutral with a $2 price target. According to management, initial results from the Phase 2 study of paxalisib plus Chimerix’s (CMRX) ONC201 for the treatment of pediatric brain cancers are expected in Q2, the analyst tells investors in a research note. The firm citers the potential of paxalisib in pediatric brain cancers, as well as potential upside in glioblastoma multiforme, for the upgrade to Buy.
Published first on TheFly
